Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019

XING Yan¹, HUA Ying-Rong², SHANG Jing³, GE Wei-Hong⁴, LIAO Jun*¹

¹School of Science, China Pharmaceutical University, Nanjing 211198, China; ²School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; ³School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 211198, China; ⁴Department of Pharmacy, Nanjing Drum Tower Hospital, Nanjing 210008, China

Available online 20 Dec., 2020

[ABSTRACT] As a representative drug for the treatment of severe community-acquired pneumonia and sepsis, Xuebijing (XBJ) injection is also one of the recommended drugs for the prevention and treatment of coronavirus disease 2019 (COVID-19), but its treatment mechanism for COVID-19 is still unclear. Therefore, this study aims to explore the potential mechanism of XBJ injection in the treatment of COVID-19 employing network pharmacology and molecular docking methods. The corresponding target genes of 45 main active ingredients in XBJ injection and COVID-19 were obtained by using multiple database retrieval and literature mining. 102 overlapping targets of them were screened as the core targets for analysis. Then built the PPI network, TCM-compound-target-disease, and disease-target-pathway networks with the help of Cytoscape 3.6.1 software. After that, utilized DAVID to perform gene ontology (GO) function enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis to predict the action mechanism of overlapping targets. Finally, by applying molecular docking technology, all compounds were docked with COVID-19 3 CL protease(3CLpro), spike protein (S protein), and angiotensin-converting enzyme II (ACE2). The results indicated that quercetin, luteolin, apigenin and other compounds in XBJ injection could affect TNF, MAPK1, IL6 and other overlapping targets. Meanwhile, anhydrosafflor yellow B (AHSYB), salvianolic acid B (SAB), and rutin could combine with COVID-19 crucial proteins, and then played the role of anti-inflammatory, antiviral and immune response to treat COVID-19. This study revealed the multiple active components, multiple targets, and multiple pathways of XBJ injection in the treatment of COVID-19, which provided a new perspective for the study of the mechanism of traditional Chinese medicine (TCM) in the treatment of COVID-19.

[KEY WORDS] Network pharmacology; Molecular docking; Xuebijing injection; COVID-19

[CLC Number] R965 [Document code] A [Article ID] 2095-6975(2020)12-0941-11

Introduction

Novel coronavirus–infected pneumonia (NCIP) was first discovered in Wuhan, Hubei Province, China in December 2019. On March 11, 2020, the World Health Organization (WHO) declared the 2019 coronavirus disease (COVID-19) is a pandemic[1]. Clinical symptoms such as fever, dyspnea, normal or decreased white blood cell count, organ dysfunction (such as shock, acute heart injury, and acute kidney injury) appear in patients, which can cause death in severe cases[3]. The incubation period of the patients from infection to onset is generally about 5.2 days and approximately 2.3% fatality rate among confirmed cases. Elderly patients as well as patients with other underlying diseases are more likely to die[3, 4]. Due to the high infectivity of the virus, it has a huge negative impact on people’s lives and the economic development of the country, but there is still a lack of special drugs and related vaccines[5]. For thousands of years, traditional Chinese medicine (TCM) has accumulated a lot of experience in the treatment of epidemics and has shown a certain effect in the treatment of infectious diseases such as severe acute respiratory syndrome and influenza A virus. Therefore, the National Health Commission and the State Administration of Traditional Chinese Medicine jointly formulated corresponding Chinese medicine diagnosis and treatment plans for the epidemic, and the TCM did show a clinical effect that was not weaker than Western medicine[6, 7].

[Received on] 30-May-2020
[Research funding] This work was supported by the Double-Class University project (No. CPU2018GY19), the National Natural Science Foundation of China (No. 81874331).
[Corresponding author] E-mail: liaojun@cpu.edu.cn
These authors have no conflict of interest to declare.
XBJ injection is the Category 2 of Traditional Chinese Medicines refined from the ancient prescription “Xuefu Zhuyu Decoction”. It is composed of five kinds of TCMs: Safflower (Honghua), Paeoniae Radix Rubra (Chishao), Ligusticum chaunxiang rhizomes (Chuanxiong), Angelica (Danggui), and Salvia miltiorrhiza (Danshen), and is mostly used clinically to treat sepsis [6], acute lung injury (ALI) [7], severe pneumonia [8], multiple organ dysfunction syndrome (MODS) [9] and other critical diseases. Recent studies have shown that XBJ injection can attenuate the excessive production of various inflammatory mediators such as IL-6, TNF-α, MCP-1, MIP-2, and IL-10 in serum and the activation of signaling pathways initiated by Pam3CSK4 [12], which played a protective role in sepsis mice. Combined with XBJ injection to treat septic shock can improve prognosis by reducing the body’s inflammatory response [13]. Besides, XBJ injection can stimulate Th17 differentiation in vitro, moderately inhibit Th17 differentiation, prevent cytokine storms, and improve the survival of patients with septic shock to a certain extent [14]. In addition, XBJ injection can prevent inflammatory reaction after Hepato-Pancreato-Biliary surgery and treat rheumatoid arthritis by regulating the inflammatory reactions of the body [15, 16]. In summary, XBJ injection has a significant anti-inflammatory effect.

XBJ injection has repeatedly appeared in the national diagnosis and treatment plan for major epidemics [17]. In the published “Diagnosis and Treatment of Novel Coronavirus Pneumonia (Trial Version Fifth, Sixth)” [18, 19], XBJ injection was listed as one of the treatment measures for severe and critical cases, and it was recommended for the mid-term clinical treatment period and severe stage. For the conventional type of COVID-19 cases, XBJ injection combined with common antiviral treatment could reduce lung lesions, improve the efficacy, and cut down the incidence of severe cases [20]. Long Wen et al. have studied the treatment of 60 severe patients with COVID-19 admitted to the North Hospital of the First Hospital of Changsha City and found that XBJ injection can effectively improve the inflammation markers and prognosis of severe COVID-19 patients [21]. XBJ injection has a positive therapeutic effect on COVID-19 cases, but its underlying mechanism remains unclear.

Network pharmacology is based on the theory of system biology. It constructs an interaction network for drugs, targets, pathways, and diseases, and then analyzes the internal correlation between them by screening key nodes. Therefore, its emphasis is the balance network (or robustness), perturbations in the network, and the biological state of drug effects rather than examining the role of a single or a few scattered targets [22]. The core ideas of the systematization and integrity of network pharmacology are consistent with the characteristics of multi-component, multi-target, and multi-mechanism of TCM [23, 24]. It has a wide range of applications in screening active ingredients, explaining the mechanism of drug action, and studying the pathogenesis of diseases [25, 26].

In this study, we aimed to screen the bioactive ingredients of XBJ injection, clarify its therapeutic targets and pathways based on a comprehensive network pharmacology-based strategy. In addition, the molecular docking method was also employed to predict the binding mode and affinity of the pharmacologically active compounds and the potential target proteins of COVID-19: 3CLpro, ACE2, and S-protein. This provides a theoretical basis for the in-depth discussion of the pharmacological mechanism of XBJ injection for COVID-19. The procedures of article were shown in Fig. 1.

Materials and Methods

**XBJ injection ingredients collection and targets fishing**

The ingredients and the corresponding target genes of XBJ injection were first collected through multiple databases. XBJ injection is composed of 5 kinds of TCM extracts of Honghua, Chishao, Chuanxiong, Danggui, and Danshen. Because of the special nature of the injection, XBJ injection does not contain all the ingredients of these five TCMs. In the early stages, other research groups used UPLC-QTOF/MS and other techniques to identify the composition of XBJ injection [27-29]. Combined with literature reports, we have screened a total of 45 compounds with high content, accurate biological activity report, and important pharmacological activity. With the help of the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, http://tcmspw.com/tcmsp.php), Traditional Chinese Medicine Integrated Database (TCMID, http://119.3.41.228:8000/tcmid/search), Encyclopedia of Traditional Chinese Medicine (ETCM, http://www.nrc.ac.cn:9090/ETCM/index.php/Home/Index/index.html), We searched putative targets of 45 compounds.

Owing to the characteristics of the database, the related targets of some compounds have not been updated or included in time. Accordingly, in the meantime, we searched literatures with the compound name plus “mechanism” or “target ” as the keywords in PubMed (https://pubmed.

---

**Fig. 1 The workflow of mechanism of XBJ Injection in the treatment of COVID-19**
struct TCM-compound-target-disease and disease-target-pathways into Cytoscape 3.6.1 software to separately construct, and disease-target-pathway networks were established. To treat COVID-19, TCM-compound-target-disease networks were created. All interactions of drugs, target genes, and diseases are studied. Network construction can filter out key nodes from the complex interaction of drugs, target genes, and diseases. All networks were visualized in Cytoscape 3.6.1 software. To explain the latent pharmacological mechanism of XBJ injection on the treatment of COVID-19, TCM-compound-target-disease, and disease-target-pathway networks were established. Imported the names of diseases, compounds, core targets, and pathways into Cytoscape 3.6.1 software to separately construct TCM-compound-target-disease and disease-target-pathway networks.

Moreover, the “network analyzer” plug-in was applied to calculate the network topology parameters of the nodes, mainly considering the Betweenness Centrality, Closeness Centrality, and degree. It is generally believed that nodes with larger parameters might be meaningful compounds or targets and act a pivotal part in the entire biological network. PPI network construction
Proteins tend to form macromolecular complexes through interactions to perform biological functions. Protein-protein interaction (PPI) network analysis helps us study the molecular mechanisms, biological processes, and functions of disease treatment from a systematic perspective. Inputted the overlapping target genes of compounds and disease into the STRING database (https://string-db.org/) to analyze the PPI between the target proteins. Set the organism to “Homo sapiens” and the scoring value (confidence) > 0.7. In order to determine the core targets of XBJ injection for COVID-19 treatment, the obtained PPI network data was imported into Cytoscape 3.6.1 software for further analysis.

Composition-target molecular docking
The studies have found that the key to the infection of human cells by the novel coronavirus (SARS-CoV-2) is the combination of the coronavirus S protein and the human ACE2 protein, which makes the virus invade the human body and cause disease [32]. 3CLpro is a key protein for viral RNA replication. Inhibiting the function of 3CLpro can block viral replication with a high probability, and indicate the direction for the development of antiviral drugs. The active ingredients in XBJ injection were docked with these three proteins. Meanwhile, drugs (remdesivir, lopinavir, ritonavir) that might be effective for the COVID-19 were considered as positive controls. First, we downloaded the pdb format files (PDB ID: 1R42, 6LU7, 6VSB) of the protein 3D structure from the RSCB PDB database (https://www.rcsb.org/), and applied the Protein Preparation Wizard module in Maestro10.1 software to process them with operations such as hydrogenation and dewater. After that, saved the files as the pdb suffix, and used the Receptor Grid Generation module to generate the grid files for docking. Downloaded the sdf files of the 3D / 2D structure of the active compounds and positive controls from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/), and pretreated ligands with the aid of the Ligprep Preparation module in Maestro10.1 software. Imported the generated protein grid files and the pre-processed ligands into the Ligand Docking module for extra precision (XP) docking. Using docking scores of the positive drugs as the reference values, screened for compounds that were superior to the reference values.

Results
Common targets of XBJ injection and COVID-19
We searched the literature using “XBJ injection constituents” as the keyword. Based on the chemical composition of XBJ injection measured in other studies, we finally determined 45 chemical components with high content, definite bio-
| Traditional Chinese Medicine | Number | Molecule Name                                      | Relative molecular mass |
|-------------------------------|--------|---------------------------------------------------|-------------------------|
| Honghua                      | CHEM1  | Luteoloside                                       | 448.38                  |
|                              | CHEM2  | Luteolin                                          | 286.25                  |
|                              | CHEM3  | Apigenin                                          | 270.25                  |
|                              | CHEM4  | Uridine                                           | 244.20                  |
|                              | CHEM5  | Quercetin                                         | 302.25                  |
|                              | CHEM6  | Protocatechuenic acid                             | 154.12                  |
|                              | CHEM7  | Caffeic acid                                      | 180.17                  |
|                              | CHEM8  | Rutin                                             | 610.57                  |
|                              | CHEM9  | Kaempferol                                        | 286.23                  |
|                              | CHEM10 | Gallic acid                                       | 170.13                  |
|                              | CHEM11 | 5-hydroxymethyl furfural                          | 126.20                  |
|                              | CHEM13 | Crocin                                            | 976.96                  |
|                              | CHEM14 | Safflower yellow A                                | 610.518                 |
|                              | CHEM25 | Guanosine                                         | 283.24                  |
|                              | CHEM26 | Hydroxysafflor yellow A                           | 612.59                  |
|                              | CHEM27 | Chlorogenic acid                                  | 354.31                  |
|                              | CHEM29 | Naringenin                                        | 272.25                  |
|                              | CHEM45 | Anhydrosafflor yellow B                           | 1044.9                  |
| Chishao                       | CHEM6  | Protocatechuenic acid                             | 154.12                  |
|                              | CHEM9  | Kaempferol                                        | 286.23                  |
|                              | CHEM10 | Gallic acid                                       | 170.13                  |
|                              | CHEM12 | Paeonol                                           | 166.19                  |
|                              | CHEM16 | Paeoniflorin                                      | 480.45                  |
| Chuanxiong                   | CHEM17 | Albiflorin                                        | 480.46                  |
|                              | CHEM18 | Galloylpaeanolflorin                              | 632.57                  |
|                              | CHEM19 | Oxidized paeanolflorin                            | 496.51                  |
|                              | CHEM29 | Naringenin                                        | 272.25                  |
|                              | CHEM31 | Catechin                                          | 290.28                  |
|                              | CHEM32 | Matrine                                           | 248.36                  |
|                              | CHEM33 | Benzoylpaeanolflorin                              | 584.57                  |
| Danshen                      | CHEM2  | Luteolin                                          | 286.25                  |
|                              | CHEM3  | Apigenin                                          | 270.25                  |
|                              | CHEM6  | Protocatechuenic acid                             | 154.12                  |
|                              | CHEM7  | Caffeic acid                                      | 180.17                  |
|                              | CHEM15 | Protocatechuenic aldehyde                         | 138.13                  |
|                              | CHEM31 | Catechin                                          | 290.28                  |
|                              | CHEM34 | Salvinanolic acid B                               | 718.66                  |
|                              | CHEM35 | Cryptotanshinone                                  | 296.39                  |
|                              | CHEM36 | Danshensu                                         | 198.17                  |
|                              | CHEM37 | Salvinanolic acid A                               | 494.48                  |
|                              | CHEM38 | Salvinanolic acid C                               | 492.44                  |
|                              | CHEM39 | Tanshinone IIA                                    | 294.34                  |
|                              | CHEM40 | Tanshinone I                                      | 276.29                  |
|                              | CHEM42 | Rosmarinic acid                                   | 360.34                  |
|                              | CHEM43 | Danshensu sodium                                  | 220.16                  |
|                              | CHEM3  | Apigenin                                          | 270.25                  |
|                              | CHEM6  | Protocatechuenic acid                             | 154.12                  |
|                              | CHEM7  | Caffeic acid                                      | 180.17                  |
logical activity reports, and important pharmacological activities. The information about compounds in each TCM is shown in Table 1.

Employing the TCMSP, TCMID, ETCM, and GeneCards platforms, the known and predicted targets of 45 compounds and COVID-19 were retrieved. Then, through the search of literature, experimentally proven human targets directly affected by 45 compounds and COVID-19 were also included. The original data source is shown in Fig. 2A. The specific target gene data sources of XBJ injection are shown in supplemental file 1, and details of COVID-19 related target genes are shown in supplemental file 2. After removing the duplicate data, a total of 408 targets related to XBJ injection and 265 targets related to COVID-19 were obtained. Among them, XBJ injection and COVID-19 had a total of 102 coincident targets (Fig. 2B), which became the focus of our follow-up analysis.

Go and KEGG pathway enrichment analysis

102 overlapping targets were performed for enrichment analysis using the DAVID online tool. GO functional enrichment analysis yielded 217 GO results ($P < 0.05$), including 162 biological process (BP) results, 22 cell composition (CC) results, and 33 molecules function (MF) results, accounting for 75%, 10%, and 15%, respectively. The top-ranked GO enrichment pathways including extrinsic apoptotic signaling pathway in absence of ligand, inflammatory response, lipopolysaccharide-mediated signaling pathway, intrinsic apoptotic signaling pathway in response to DNA damage, etc. 117 pathways were screened by KEGG enrichment results ($P < 0.05$). Screened the top 20 KEGG results and the top 10 BP, CC, MF results in GO annotation analysis according to the $P$-value and visualized them separately with the R software package. The results are shown in Figs. 3A, B.

As shown in Figs. 3A, B, a variety of pathways which related to inflammation and immune response were significantly enriched, such as the TNF signaling pathway, inflammatory bowel disease (IBD) pathway, the Toll-like receptor signaling pathway, the Hypoxia-inducible factor (HIF)-1 signaling pathway, the P13K-AKT signaling pathway, the MAPK signaling pathway, apoptosis, and the Nucleotide-binding oligomerization domain (NOD)-like receptor signaling pathway. The enrichment level of pathways related to

| Traditional Chinese Medicine | Number | Molecule Name     | Relative molecular mass |
|-----------------------------|--------|-------------------|-------------------------|
| CHEM10                      |        | Gallic acid       | 170.13                  |
| CHEM21                      |        | n-Butylidenephthalide | 188.22                  |
| CHEM22                      |        | Levistolide A     | 380.48                  |
| CHEM23                      |        | Ligustrazine       | 136.19                  |
| CHEM30                      |        | Senkyunolide H    | 224.25                  |
| CHEM44                      |        | Senkylnolide I    | 204.24                  |
| Danggui                     | CHEM4  | Uridine           | 244.20                  |
| CHEM7                       |        | Caffeic acid      | 180.17                  |
| CHEM20                      |        | Hypericin         | 504.4                   |
| CHEM24                      |        | Ferulic acid      | 194.20                  |
| CHEM25                      |        | Guanosine         | 283.24                  |
| CHEM28                      |        | Ethyl ferulate    | 222.24                  |
| CHEM41                      |        | Ligustilide       | 190.24                  |

Fig. 2   (A) Data sources of active compounds in XBJ injection. 29%, 14%, 46% and 11% of the data were separately from PubMed, TCMSP, ETCM and TCMID. (B) Identification of overlapping targets of COVID-19 and XBJ injection. 102 overlapping targets were obtained from XBJ injection and COVID-19
regulating viral infections was also unignored. Those pathways involved hepatitis B, hepatitis C, influenza A, and Epstein-Barr virus infection. Furthermore, it also showed a certain degree of enrichment in cancer pathways and other infectious lung diseases such as pertussis, tuberculosis. Therefore, we inferred that XBJ injection might be beneficial to the treatment of COVID-19 by regulating inflammation and immune regulation related pathways, viral infection related pathways.

Fig. 3 Enrichment analysis results of core targets in XBJ injection. (A) Top 10 BP, CC and MF results in GO annotation analysis. The y-axis stands for enriched GO of the targets, and the x-axis stands for the gene number in the GO annotation results. (B) Top 20 KEGG pathway enrichment bubble diagram (P < 0.05). The y-axis stands for enriched pathways of the targets, and the x-axis stands for the values of fold enrichment.

Network construction and analysis

Cytoscape 3.6.1 software was employed to draw the TCM-compound-target-disease and disease-target-pathway networks (See Figs. 4A, B). The TCM-compound-target-disease network comprised a total of 153 nodes (1 disease node, 5 medicinal materials nodes, 42 compound nodes, 105 target nodes) and 599 edges, of which compounds such as danshensu sodium, galloylpaeoniflorin and anhydrosafflor yellow B had not found their corresponding targets. These inter-
actions indicated that one compound was able to modulate many targets, and one target was capable of being modulated by multiple compounds simultaneously. According to the node degree parameters of the nodes in the network (shown in Table 2), the top five compounds in the network were quercetin (CHEM5), luteolin (CHEM2), apigenin (CHEM3), Naringenin (CHEM29), Gallic acid (CHEM10), and could interact with 52, 35, 34, 26, 25 targets respectively. From the perspective of the target, the top 5 were TNF, PTGS2, CASP3, BAX, and HMOX1, which could interact with 22, 21, 21, 19, 19 compounds respectively.

For further analysis, sorted by the corrected $P$-value, that was, FDR value, the top 10 KEGG pathways and GO annotation results were added into disease-target-pathway networks. As can be seen from the network, the targets of COVID-19 were coordinated and controlled by multiple pathways. The pathway with the most enriched genes was the pathways in cancer, with 32 genes, followed by the Hepatitis B pathway and extracellular space annotation with 28 genes and 23 genes respectively.

**PPI network analysis**

Studying the interaction network between proteins helps to mine the core regulatory genes. Entered 102 overlapping targets related to COVID-19 and XBJ injection into the STRING database to construct the PPI network (See Fig. 5A). The network had 94 nodes and 779 interaction relationships, with an average degree value of 16.6. Then used Cytoscape 3.6.1 for visual processing, and applied the Degree descending arrangement in the CytoHubba plugin to filter out 40 core targets that were greater than the average degree value. The top ten target proteins are shown in Fig. 5B. Combining PPI network, TCM-compound-target-disease, and disease-target-pathway networks through Merge function in Cytoscape 3.6.1(results see Table 3), the results suggested that TNF, MAPK1, IL6, and other genes might play an important role in the treatment of COVID-19.

**Analysis of molecular docking results**

Molecular docking results revealed that most of the active compounds in XBJ injection had a good binding activity with ACE2, 3CLpro, and S protein. Table 4 evinced the

| Names on the network | Betweenness Centrality | Closeness Centrality | Degree | Name       |
|----------------------|------------------------|----------------------|--------|------------|
| CHEM5               | 0.0851                 | 0.4750               | 52     | Quercetin  |
| CHEM2               | 0.0299                 | 0.4222               | 35     | Luteolin   |
| CHEM3               | 0.0456                 | 0.4294               | 34     | Apigenin   |
| CHEM29              | 0.0277                 | 0.4086               | 26     | Naringenin |
| CHEM10              | 0.0335                 | 0.4108               | 25     | Gallic acid|
| CHEM9               | 0.0170                 | 0.3979               | 24     | Kaempferol |
| CHEM40              | 0.0158                 | 0.3838               | 20     | Tanshinone I |
| CHEM25              | 0.0166                 | 0.3819               | 18     | Guanosine  |
| CHEM24              | 0.0134                 | 0.3838               | 18     | Ferulic acid|
| CHEM42              | 0.0101                 | 0.4234               | 17     | Rosmarinic acid |

![Fig. 5](image)  
**Fig. 5**  
PPI network construction. (A) PPI network of overlapping targets of XBJ injection and COVID-19. (B) Core genes of identified targets. Among all the core targets, the darker the red, the more important it was.
docking scores of the three positive drugs, the top three compounds in the network, and the top three compounds with the best binding with the three proteins. The docking results of them are shown in Fig. 6. The results of molecular docking of all compounds are shown in supplemental file 3. Taking the docking score of the positive drugs as a control, the more negative the score, the better the docking result between the compound and the protein. The top three compounds in the network analysis results, which were quercetin, luteolin, and apigenin, all had similar docking scores as positive drugs but not reached the ideal value. The docking scores of AHSYB, SAB, and rutin were significantly higher than those of the positive control. It demonstrated that the compounds that were not ranked very high in the network may also be the active ingredients of XBJ injection for COVID-19.

**Discussion**

Since the outbreak of COVID-19 in December 2019, a total of more than 80,000 people has been diagnosed in China. As of May 11, 2020, there were more than 3 million confirmed cases outside China [33]. The effectiveness of TCM on the treatment of epidemics is well documented. In the SARS period, TCM as a supplementary means made a significant contribution. Moreover, in the treatment of COVID-19, TCM has played a role that cannot be ignored. It has been reported that the use of TCM to treat 102 patients with mild symptoms has shortened the disappearance of clinical symptoms and the recovery time of body temperature. The average length of hospitalization and the incidence of severe cases were significantly reduced, and the improvement rate of CT image was increased [34].

The initial symptoms of COVID-19 are not obvious, mainly manifested as no symptoms or fever, dry cough, and fatigue. However, about 75% of the patients can develop into serious diseases, which accompanied by dyspnea and severe

### Table 3  Node parameters of Merge network for XBJ injection

| Names on the network | Betweenness Centrality | Closeness Centrality | Degree | Name                          |
|----------------------|------------------------|----------------------|--------|-------------------------------|
| TNF                  | 0.2156                 | 0.6705               | 78     | Tumor necrosis factor         |
| MAPK1                | 0.0536                 | 0.6201               | 75     | Mitogen-activated protein kinase 1 |
| IL6                  | 0.0487                 | 0.6201               | 73     | Interleukin-6                 |
| MAPK3                | 0.0334                 | 0.6092               | 63     | Mitogen-activated protein kinase 3 |
| RELA                 | 0.0307                 | 0.5904               | 62     | Transcription factor p65      |
| PTGS2                | 0.0395                 | 0.5904               | 58     | Prostaglandin G/H synthase 2   |
| CASP3                | 0.0338                 | 0.5825               | 57     | Caspase-3                     |
| TP53                 | 0.0310                 | 0.5786               | 57     | Cellular tumor antigen p53    |
| MAPK8                | 0.0301                 | 0.5786               | 56     | Mitogen-activated protein kinase 8 |
| IL1B                 | 0.0200                 | 0.5805               | 51     | Interleukin-1 beta            |

### Table 4  Molecular docking score of active components in XBJ injection and positive drugs

| Chemical Name         | ACE2   | 3CLpro | Spike Protein |
|-----------------------|--------|--------|---------------|
| Ritonavir             | −5.092 | −4.228 | −7.954        |
| Lopinavir             | −5.561 | −6.114 | −8.594        |
| Remdesivir            | −6.03  | −8.1   | −9.714        |
| Quercetin             | −5.898 | −7.775 | −8.572        |
| Luteolin              | −6.258 | −6.84  | −7.838        |
| Apigenin              | −4.34  | −6.112 | −6.322        |
| Anhydrosafflor yellow B | −10.796 | −11.184 | −17.205    |
| Salvianolic acid B    | −7.576 | −11.261 | −14.563      |
| Rutin                 | −7.069 | −9.888 | −14.044       |

Fig. 6 Molecular docking results of the three positive drugs, the top 3 compounds in the network, and top 3 compounds with the best binding. A yellow object represents a compound and the surrounding chain represents an anti-inflammatory target.
pulmonary infection, such as acute respiratory distress syndrome (ARDS), sepsis and so on. So, at this stage, the death rate of patients is very high, which is about 15% \[35\]. XBJ injection is listed as one of the treatment measures for the severe and critical case and a lot of evidence has shown that XBJ injection has a significant anti-inflammatory effect. For instance, XBJ injection is the only Chinese patent medicine approved in China for the treatment of sepsis which can treat sepsis by reducing inflammatory reaction \[8, 12\]. Meanwhile, ARDS and multiple organ failure in severe patients of COVID-19 were reported to be associated with excessive inflammation and cytokine storms \[16\]. Therefore, XBJ injection may intervene to treat COVID-19 by regulating inflammation and immune response. Among the 5 Chinese herbal medicine ingredients of XBJ injection, the main components of Honghua include apigenin, safflower yellow A, quercetin, etc. It is reported that Honghua can play a pivotal role in the prevention of ALI and other inflammatory lung diseases though regulating Nrf2 \[37\]. The main components of Chishao are paeonol, paeonol, gallic acid, etc. In particular, paeonol is the most abundant compound in XBJ injection. Paeonol can exert therapeutic effect on sepsis via decreasing plasma stREM-1 level and inflammatory response \[38\]. Chuanxiong contains components such as ligustrazine, apigenin, butylphthalide, and so on. Among them, Ligustrazine could ameliorate the inflammatory damage through inhibiting the Rho/ROCK pathway, thereby interfering with the endothelial dysfunction treatment in ALI \[39\]. Besides, cryptotanshinone, as a component of Danshen, had antitumor activity by inducing the immune response of the body, and also had a certain therapeutic effect on pulmonary fibrosis \[40, 41\]. In summary, XBJ injection can exert anti-inflammatory effects through a variety of components, which has a significant impact on lung inflammatory diseases.

According to the results of network analysis, TNF, MAPK1, and IL-6 might be the crux in the treatment of COVID-19, and all of them were the targets of quercetin, luteolin, and apigenin. IL-6 is a versatile cytokine with a wide range of functions. It has the functions of regulating immune response, acute phase response, and tissue damage, and participates in the anti-infective immune response of the body \[42\]. Drugs targeting IL-6 or down-regulating IL-6, such as tocilizumab and sarilumab, might be effective in blocking inflammatory storms, so they could become the promising treatment for patients with COVID-19 \[43, 44\]. Mitogen-activated protein kinase (MAPK) has been reported as a key regulator of ALI \[45\]. Mechanistically, MAPK1 could achieve the purpose of treating cell injury and lung injury by decreasing cell inflammation and apoptosis. At the same time, studies have suggested that medicines targeting the MAPK3/MAPK1 signaling pathway may have crucial value in the treatment of various inflammatory diseases \[46, 47\]. Tumor necrosis factor alfa (TNFα) is present in the blood and diseased tissues of patients with COVID-19, and TNFα levels are much higher in patients with severe diseases \[46\]. TNF could activate IL-6 and IL-1, meanwhile, anti-TNF could decrease leucocyte traffic to inflamed tissues by reducing adhesion molecules and chemokines \[46, 49\]. Thus TNF, as an essential target, is able to contribute to the immunotherapy of COVID-19 \[40, 50\]. Besides, in severe patients, serum levels of IL-2, IL-7, IL-10, GSCF, IP10 (CXCL10), MCP1 (CCL2), and MIP1A (CCL3) were significantly higher than that of non-severe patients \[35, 52, 53\]. Therefore, the ingredients in XBJ injection are capable of subsiding the inflammatory response by reducing the concentration of the following factors in serum: IL-1B, IL-2, IFNG, TNF-α, CXCL10, CCL2, IL10, IL-17, IL-8. KEGG enrichment results showed that TNF, MAPK1, and IL-6 can be enriched to the following pathways: TNF signaling pathway, Influenza A, Tuberculosis, Toll-like receptor signaling pathway, PI3K-Akt signaling pathway, and NOD-like receptor signaling pathway, which suggested that XBJ injection might target IL6, MAPK1, and TNF through quercetin, luteolin, and apigenin, and then affected inflammation, immune regulation, and viral infection related pathways, played an anti-inflammatory effect to treat COVID-19.

The interaction between the viral S protein and ACE2 on the surface of the host cell is important because ACE2 can participate in the regulation of the renin-angiotensin system to trigger lung inflammation. 3CLpro, a viral protease, was regarded as the target of COVID-19 and used to find many potential compounds, such as lopinavir. Therefore, these three are regarded as ideal targets for the treatment of COVID-19 \[40\]. Among the molecular docking results of all compounds with 3CLpro, S protein, and ACE2, the three compounds with the highest scores were AHSYB, SAB, and rutin. After searching the database, we found that there was little information about the potential target of AHSYB, which indicated that there were few studies on its pharmacological activities. However, with safflor yellow A and hydroxysafflor yellow A, it can ameliorate the lung inflammation and damage caused by lipopolysaccharide through inhibiting the formation of the neutrophil extracellular trap (NET) \[53\]. SAB, a water-soluble component of Danshen, usually exists in the form of magnesium salt, namely magnesium lithospermate B. It has been reported that magnesium lithospermate B and rosmarinic acid can exert antiviral effect through reducing the propagation of Enterovirus 71(EV71) particles \[56\]. In the past studies, rutin, in addition to its well-known antioxidant activity, has shown a good inhibitory effect on hepatitis C virus (HCV), EV71, and other viruses \[57, 58\]. The above results indicated that AHSYB, SAB, and rutin in XBJ injection might be useful in the treatment of COVID-19 by inhibiting virus invasion and replication.

However, due to the lack of understanding of viruses, disease complications, there are some deficiencies in our study, such as the lack of in-depth research on the predictive ingredients and core targets and pathways. Thus, further investigation and relevant validation in vivo and in vitro are needed.

**Conclusion**

In this study, network pharmacology and molecular
docking technology were used to explore the potential regulatory mechanism of XBJ injection in the treatment of COVID-19. It is suggested that XBJ injection may affect IL-6, TNF, and MAPK1 targets through quercetin, luteolin, and apigenin to inhibit excessive inflammation and cytokine storm caused by COVID-19. The role of XBJ injection involves a variety of biological processes, mainly signaling pathways such as the TNF signaling pathway, Influenza A, Tuberculosis, Toll-like receptor signaling pathway, PI3K-Akt signaling pathway, and so on. Meanwhile, AHSYB, SAB, and rutin suppressed the invasion and replication of novel coronavirus, which will play a role in the treatment of COVID-19. It embodies the therapeutic effect of XBJ injection on COVID-19 with the multi-component, multi-target, and multi-channel.

References

[1] Hol TF, Chan KKH, Chung VCH, et al. Highlights of traditional Chinese medicine frontline expert advice in the China national guideline for COVID-19 [J]. Eur J Integr Med, 2020 : 101116, in press.
[2] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [J]. JAMA, 2020, 323(11): 1061-1069.
[3] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. J Lancet, 2020, 395(10233): 507-513.
[4] Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia [J]. N Engl J Med, 2020, 382(13): 1199-1207.
[5] Lake MA. What we know so far: COVID-19 current clinical knowledge and research [J]. Clin Med (Lond), 2020, 20(2): 124-127.
[6] Yang Y, Islam MS, Wang J, et al. Traditional Chinese Medicine in the treatment of patients infected with 2019-new coronavirus (SARS-CoV-2): a review and perspective [J]. Int J Biol Sci, 2020, 16(10): 1708-1717.
[7] Shi J, Yang ZG, Ye C, et al. Clinical observation on 49 cases of non-critical COVID-19 in Shanghai treated by integrated traditional Chinese and western medicine [J]. Shanghai J Tradit Chin Med, 2020, 54(04): 30-35.
[8] Liu S, Yao G, Zhang J, et al. Efficacy of Xuebijing Injection for Sepsis (EXIT-SEP): protocol for a randomised controlled trial [J]. BMJ Open, 2019, 9(8): e028664.
[9] Xu Z, Liu D, Li K, et al. To explore the preventive and therapeutic effects of Xuebijing injection on acute lung injury induced by cardiopulmonary bypass in rats by regulating the expression of microRNA-17-5p and its mechanism [J]. Chin Crit Care Med, 2019, 31(7): 867-872.
[10] Wang P, Song Y, Liu Z, et al. Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial [J]. Trials, 2016, 17(1): 142.
[11] Song R, Dong C, Wang C, et al. Effectiveness of Xuebijing injection in treatment of multiple organ dysfunction syndrome: a Meta analysis [J]. Chin Crit Care Med, 2018, 30(9): 848-854.
[12] Li T, Qian Y, Miao Z, et al. Xuebijing Injection alleviates Pam3CSK4-induced inflammatory response and protects mice from sepsis caused by methicillin-resistant staphylococcus aureus [J]. Front Pharmacol, 2020, 11: 104.
[13] Sun R, Liang M, Yang H, et al. Effect of Xuebijing on inflammatory response and prognosis in patients with septic shock [J]. Chin Crit Care Med, 2020, 32(4): 455-462.
[14] Chen X, Feng Y, Shen X, et al. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro-and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis [J]. J Ethnopharmacol, 2018, 211: 358-365.
[15] Zhang Q, Li J, Liang X, et al. The preventive effect of Chinese herbal preparation Xuebijing against hyperactive inflammation after heptato-pancreato-biliary surgery [J]. Ann Transl Med, 2019, 7(18): 481.
[16] Li S, Wang H, Sun Q, et al. Therapeutic effect of Xuebijing, a Traditional Chinese Medicine Injection, on rheumatoid arthritis [J]. Evid Based Complement Altern Med, 2020, 2020: 2710782.
[17] Li CY, Zhang XY, Liu S, et al. Current evidence and research prospects of Xuebijing Injection in treating novel Coronavirus-infected Pneumonia (COVID-19) [J]. World Sci Technol Mod Tradit Chin Med, 2020, 22(2): 1-6.
[18] Guidelines on diagnosis and treatment of novel coronavirus pneumonia (Trial sixth edition) [J]. Chin J Infect Control, 2020, 19(02): 192-195.
[19] Guidelines on diagnosis and treatment of novel coronavirus pneumonia (Trial fifth edition) [J]. Chin J Integr Tradit West Med, 2020, 40(02): 136-138.
[20] Zhang CY, Zhang S, Wang W, et al. Clinical observation of Xuebijing in the treatment of COVID-19 [J]. Chin J Hosp Pharm, 2020, 40(9): 964-967.
[21] Wen L, Zhou Z, Jiang D, et al. Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019 [J]. Chin Crit Care Med, 2020, 32(4): 426-429.
[22] Yuan H, Ma Q, Cui H, et al. How can synergism of traditional medicines benefit from network pharmacology? [J]. Molecules, 2017, 22(7): 1135.
[23] Hopkins AL. Network pharmacology: the next paradigm in drug discovery [J]. Nat Chem Biol, 2008, 4(11): 682-690.
[24] Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application [J]. Chin J Nat Med, 2013, 11(2): 110-120.
[25] Huang XF, Cheng WB, Jiang Y, et al. A network pharmacology-based strategy for predicting anti-inflammatory targets of ephedra in treating asthma [J]. Int Immunopharmacol, 2020, 83: 106423.
[26] Chen J, Wang YK, Gao Y, et al. Protection against COVID-19 injury by qingfei paiku decoction via anti-viral, anti-inflammatory activity and metabolic programming [J]. Biomed Pharmacother, 2020, 129: 110281.
[27] Huang H, Li L, Song S, et al. Identification of the major constituents in Xuebijing injection by HPLC-ESI-MS [J]. Phytochem Anal, 2011, 22(4): 330-338.
[28] Sun Z, Zuo L, Sun T, et al. Chemical profiling and quantification of XueBuJing injection, a systematic quality control strategy using UHPLC-Q Exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry [J]. Sci Rep, 2017, 7(1): 16921.
[29] Tu YR, Ouyang HZ, Sun MJ, et al. Simultaneous identification of 20 components in Xuebijing injection, a systematic quality control method of XuebiJing injection, a systematic quality control strategy using UHPLC-Q Exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry [J]. Curr Protoc Bioinformatics, 2016, 54: 1-33.
[30] Stelzer G, Rosen N, Plaschkes I, et al. The genecards suite: from gene data mining to disease genome sequence analyses [J]. Curr Protoc Bioinformatics, 2016, 54: 1-33.
[31] Dennis G, Sherman BT, Hosack DA, et al. DAVID bioinformatics resources: expanded annotation database and novel algorithms to better extract biology from large gene lists [J]. Nucleic Acids Res, 2007, 35(Web Server issue): W169-175.
[32] Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation [J]. Science, 2020, 367(6483): 1260-1263.
[33] Coronavirus disease (COVID-19) situation report–111 [R]. World Health Organization, 2020.
Chang J, Wang H, Gao C, et al. Traditional Chinese medicine for COVID-19 treatment [J]. *Pharmacol Res*, 2020, **155**: 104743.

Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. *Lancet*, 2020, **395**(10223): 497-506.

Ren Y, Yao MC, Huo XQ, et al. Study on treatment of “cytokine storm” by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway [J]. *Zhongguo Zhong Yao Za Zhi*, 2020, **45**(6): 1225-1231.

Kim J, Woo J, Lyu JH, et al. Carthari Flos suppresses neutrophil lung inflammation in mice, for which nuclear factor-erythroid 2-related factor-1 is required [J]. *Phytochemistry*, 2014, **81**(4): 470-478.

Liu XR, Xu J, Wang YM, et al. The effects of paoniflorin injection on soluble triggering receptor expressed on myeloid-1 (sTREM-1) levels in severe septic rats [J]. *Korean J Physiol Pharmacol*, 2016, **20**(6): 565-571.

Chen J, Wang H, Gao C, et al. Tetramethylpyrazine alleviates LPS-induced inflammatory injury in HUVECs by inhibiting Rho/ROCK pathway [J]. *Biochem Biophys Res Commun*, 2019, **514**(1): 329-335.

Zhang Y, Lu W, Zhang X, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and Rho/ROCK pathway [J]. *Cancer Immunol Immunother*, 2019, **68**(7): 1059-1071.

Bizzarri M, Lagana AS, Aragona D, et al. Insolitol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2? [J]. *Eur Rev Med Pharmacol Sci*, 2020, **24**(6): 3426-3432.

Zhang Y, Zhong Y, Pan L, et al. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? [J]. *Drug Discov Ther*, 2020, **14**(2): 100-102.

Alijotas-reig J, Esteve-val E, Belizna C, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review [J]. *Autoimmun Rev*, 2020, 102569, in press.

Zhu S, Song W, Sun Y, et al. MiR-342 attenuates lipopolysaccharide-induced acute lung injury via inhibiting MAPK1 expression [J]. *Clin Exp Pharmacol Physiol*, in press.

Di R, Crisafulli C, Mazzon E, et al. Effect of PD98059, a selective MAPK3/MAPK1 inhibitor, on acute lung injury in mice [J]. *Int J Immunopharmacol*, 2009, **22**(4): 937-950.

Lara PC, Burgos J, Macias D. Low dose lung radiotherapy for COVID-19 pneumonia. The rationale for a cost-effective anti-inflammatory treatment [J]. *Clin Transl Radiat Oncol*, 2020, **23**: 27-29.

Daret PM, Sebbag E, Mallick A, et al. Recovery from COVID-19 in a patient with spondyloarthritides treated with TNF-alpha inhibitor etanercept [J]. *Ann Rheum Dis*, in press. https://doi.org/10.1136/annrheumdis-2020-217362

Tursi A, Vetroni LM, Papa A. Anti-TNF-alpha agents in inflammatory bowel disease and course of COVID-19 [J]. *Inflamm Bowel Dis*, 2020, izaa114, in press. https://doi.org/10.1093/ibd/izaa114

Chiappelli F, Khakshooy A, Greenberg G. CoVID-19 Immunopathology and Immunotherapy [J], *Bioinformation*, 2020, **16**(3): 219-222.

Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions [J]. *Autoimmun Rev*, 2020, 102567, in press. https://doi.org/10.1016/j.autrev.2020.102567

Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib [J]. *J Microbiol Infectool Infect*, 2020, S1664-1182(20)30065-7, in press. https://doi.org/10.1016/j.jmi.2020.03.005

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak [J]. *J Autoimmun*, 2020, **109**: 102433.

Liu C, Zhou Q, Li Y, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases [J]. *ACS Cent Sci*, 2020, **6**(3): 315-331.

Dong YP, Guo Y, Wen PS, et al. Three ingredients of safflower alleviate acute lung injury and inhibit NET release induced by lipopolysaccharide [J]. *Mediators Inflamm*, 2020, **2020**: 2720369.

ChungYC, Hsieh FC, Lin YJ, et al. Magnesium lithospermate B and rosmarinic acid, two compounds present in Salvia miltiorrhiza, have potent antiviral activity against enterovirus 71 infections [J]. *Eur J Pharmacol*, 2015, **755**: 127-133.

Lin YJ, Chang YC, Hsiao NW, et al. Fisetin and rutin as 3C protease inhibitors of enterovirus A71 [J]. *J Virol Methods*, 2012, **182**(1-2): 93-98.

Bose M, Kamra M, Mullick R, et al. Identification of a flavonoid isolated from plum (Prunus domestica) as a potent inhibitor of Hepatitis C virus entry [J]. *Sci Rep*, 2017, **7**(1): 3965.